Suppr超能文献

新型 SPLUNC1 衍生抗菌肽 α4-短肽在呼吸道感染小鼠模型中的抗菌特性和疗效。

Antibacterial Properties and Efficacy of a Novel SPLUNC1-Derived Antimicrobial Peptide, α4-Short, in a Murine Model of Respiratory Infection.

机构信息

Department of Environmental and Occupational Health, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Department of Environmental and Occupational Health, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

出版信息

mBio. 2019 Apr 9;10(2):e00226-19. doi: 10.1128/mBio.00226-19.

Abstract

Multidrug resistance (MDR) by bacterial pathogens constitutes a global health crisis, and resistance to treatment displayed by biofilm-associated infections (e.g., cystic fibrosis, surgical sites, and medical implants) only exacerbates a problem that is already difficult to overcome. Antimicrobial peptides (AMPs) are a promising class of therapeutics that may be useful in the battle against antibiotic resistance, although certain limitations have hindered their clinical development. The goal of this study was to examine the therapeutic potential of novel AMPs derived from the multifunctional respiratory host defense protein SPLUNC1. Using standard growth inhibition and antibiofilm assays, we demonstrated that a novel structurally optimized AMP, α4-short, was highly effective against the most common group of MDR bacteria while showing broad-spectrum bactericidal and antibiofilm activities. With negligible hemolysis and toxicity to white blood cells, the new peptide also demonstrated efficacy when delivered directly into the airway in a murine model of -induced respiratory infection. The data warrant further exploration of SPLUNC1-derived AMPs with optimized structures to assess the potential application to difficult-to-cure biofilm-associated infections. The rise of superbugs underscores the urgent need for novel antimicrobial agents. Antimicrobial peptides (AMPs) have the ability to kill superbugs regardless of resistance to traditional antibiotics. However, AMPs often display a lack of efficacy Sequence optimization and engineering are promising but may result in increased host toxicity. We report here the optimization of a novel AMP (α4-short) derived from the multifunctional respiratory protein SPLUNC1. The AMP α4-short demonstrated broad-spectrum activity against superbugs as well as efficacy in the pneumonia model. Further exploration for clinical development is warranted.

摘要

细菌病原体的多药耐药性(MDR)构成了全球健康危机,而生物膜相关感染(例如囊性纤维化、手术部位和医疗植入物)显示出的耐药性只会使已经难以克服的问题更加恶化。抗菌肽(AMPs)是一类很有前途的治疗药物,可能对抗生素耐药性的斗争有用,尽管某些限制阻碍了它们的临床发展。本研究的目的是研究源自多功能呼吸宿主防御蛋白 SPLUNC1 的新型 AMP 的治疗潜力。使用标准生长抑制和抗生物膜测定,我们证明了一种新型结构优化的 AMP,α4-short,对最常见的一组 MDR 细菌非常有效,同时具有广谱杀菌和抗生物膜活性。由于新肽的溶血和对白细胞的毒性可忽略不计,因此在诱导呼吸感染的小鼠模型中直接递送至气道时也表现出了疗效。这些数据证明了进一步探索具有优化结构的 SPLUNC1 衍生 AMP 的合理性,以评估其在难以治愈的生物膜相关感染中的潜在应用。超级细菌的出现突显了对新型抗菌剂的迫切需求。抗菌肽(AMPs)具有杀死超级细菌的能力,而不管其对传统抗生素的耐药性如何。然而,AMPs 通常表现出缺乏疗效。序列优化和工程是有前途的,但可能导致宿主毒性增加。我们在这里报告了一种源自多功能呼吸蛋白 SPLUNC1 的新型 AMP(α4-short)的优化。AMP α4-short 对超级细菌表现出广谱活性,并且在肺炎模型中也具有疗效。进一步的临床开发探索是必要的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fbf/6456746/1ae503540875/mBio.00226-19-f0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验